It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
www.wlox.com...
After multiple heart attacks and transplants, William Schram's life depends on at least 14 prescriptions each month. But under a new state bill, Medicaid will only cover five.
Originally posted by slank
.
If we want to speculate,
The process:
The technologies for this process are probably going to be pretty amazing.
I have images of a computer smoking as it works.
I can imagine bringing the electron field of an atom of a molecule in close proximity to another and seeing them merge, then they are rotated and a third constituent is added and a portion of one of the pieces is removed. They might use magnetic fields, enzymes and/or carbon nanotubes for this.
.
Originally posted by Astronomer68
The real question is, can a patient specific approach ever be cost-effective? Right now, I'de have to say it would not be cost-effective
and I don't see how that could change until at least three things are available: 1. The capability to accurately scan & measure the current cellular physiology of an individual relatively cheaply., 2. Far more extensive knowledge of the proteins manufactured by our genes., and 3. The local (or at most regional) capability to actually formulate & manufacture the required medications. Seems to me (3) would pretty much have to be an automated process or it would be cost prohibitive. All-in-all, I don't see this kind of thing happening anytime soon.
Originally posted by soficrow
The "cost-effective" argument is invalid - it does not accommodate any information except direct healthcare costs. ....The costs of economic/social impacts already are staggering. The costs of ignoring these impacts will bankrupt the nation - and lead to backward eugenics-genetics policies, and euthanasia.
Originally posted by Astronomer68
Originally posted by soficrow
The "cost-effective" argument is invalid - it does not accommodate any information except direct healthcare costs. ....The costs of economic/social impacts already are staggering. The costs of ignoring these impacts will bankrupt the nation - and lead to backward eugenics-genetics policies, and euthanasia.
I believe the cost-effective argument is valid. Quantification of lost productivity, social impacts, etc. are notoriously difficult to reach agreement on.
the cost to formulate and manufacture patient specific medications would be relatively easy to quantify and be very visible. Further, the latter costs would be concentrated in a relatively small segment, which for ease of expression I'll just call the drugs industry, and those costs would be seen as prohibitively high on a per patient basis.
I find it difficult to believe insurance companies, medicare and medicaid would be willing to absorb those costs.
Granted, the present way of treating patients may be more expensive overall (especially in the long run), but those costs are spread out and largely invisible to most americans.
...Most of the time the true cost of the cheaper tool would turn out to be higher than the cost of the specialized tool. My belief is that the same situation would exist concerning patient specific drugs (at least at the present time).
Originally posted by Red Golem
Soficrow,
the these blocked testing and treatments for the health conditions that you menchened being used to any extent in other countries?
Originally posted by nilknok37
Suggestion: Search for med pros who stress "cellular" vs. "organ" health, I.e., as advocated by the late Linus Pauling, PhD.
Originally posted by nilknok37
Suggestion: Search for med pros who stress "cellular" vs. "organ" health, I.e., as advocated by the late Linus Pauling, PhD.
Originally posted by nilknok37
Suggestion: Search for med pros who stress "cellular" vs. "organ" health, I.e., as advocated by the late Linus Pauling, PhD.